Hello again, myeloma world.

Today's review of myeloma-related research and news covers a particu­larly wide range of topics.

We start our review with a quick look at a new study related to Pomalyst and its use in heavily pretreated multiple myeloma patients. (The Beacon published a separate article about this study earlier today.)

Next, we report on changes the U.S. Food and Drug Admin­istra­tion has made in the procedures for “com­passion­ate use” access to unapproved drug treat­ments, including potential new myeloma therapies.

We then turn to discussion of a European study …

How has your week been, myeloma world?

Summer definitely is here at Myeloma Morning Headquarters. We had temper­a­tures yesterday and today that rival those normally seen in early August.

We're not exactly sure how we feel about this devel­op­ment.

As for myeloma-related news, we have a lot of ground to cover.

We have one new myeloma research study that we summarize at length. It's about a difficult subject, namely, the impact of early relapse on the over­all survival of multiple myeloma patients. It's a difficult subject be­cause, not surprisingly, early re­lapse con­tinues …

Good morning, myeloma world.

We hope you had a pleasant weekend and that your new week is off to a good start.

The big news today is that Darzalex (daratumumab) has been approved in Europe as a new treatment for multiple myeloma. We will be pub­lish­ing a separate news article on the approval, which was announced a few hours ago. In the mean­time, you can find information about the approval in this press release from Genmab, the company that initially developed Darzalex.

The other news we have for you …

Good morning, myeloma world.

Since the last edition of Myeloma Morning, abstracts for two im­por­tant upcoming medical meetings have been made public: the American Society of Clinical Oncology (ASCO) annual meeting, which will take place June 3 through June 7 in Chicago, and the European Hematology Association (EHA) annual congress, which is scheduled for June 9 through June 12 in Copenhagen, Denmark.

The publication of the abstracts and the meetings themselves mean that there is going to be a lot of multiple myeloma-related news in the coming weeks. We will do our …

Hello, myeloma world.

We hope your week has gotten off to a great start.

We're looking forward to reviewing three new myeloma-related research studies with you today.

The first study we summarize in today's report focuses on the survival of older blood cancer patients, including (of course) older multiple myeloma patients.

The second study presents the results of the CHAMPION-1 clinical trial, which tested once weekly Kyprolis in com­bi­na­tion with dexa­meth­a­sone in re­lapsed multiple myeloma patients.

The final study we review is a detailed look at an important Revlimid-related side effect – …

It's good to see you again, myeloma world.

We got tied up the past couple days with, among other things, coverage of the Empliciti approval in Europe. But we're glad to be back and we have two new research studies that we'd like to discuss with you.

First, we take a look at an Israeli study that does a deep dive into the t(11;14) chro­mosomal abnormality in newly diagnosed multiple myeloma patients. The focus of this particular deep dive is the impact other chro­mosomal abnormalities have on the prognosis of newly …

How has your week started, myeloma world?

We hope it's going well so far.

We once again have a rather long list of new myeloma research we'd like to discuss with you. We sus­pect most of our readers will find at least one or two studies in the report to be of particular interest.

We begin today's report with a discussion of a somewhat rare eye-related side effect of Velcade (bor­tez­o­mib) and a possible way to control the side effect.

Next, we take a quick look at two articles about …